Children's Cancer Therapy Development Institute

cc-TDI is on an exciting journey of research progress, and we are seeking an exceptional Operations Manager to join our dynamic and passionate team in Hillsboro, Oregon. As the Operations Manager, you will play a crucial role in driving the efficiency and effectiveness of our organization’s operations, ensuring smooth day-to-day functioning that align with cc-TDI’s strategic goals. Working closely with the Executive Director and leadership team, you will contribute to the long-term vision and strategy of cc-TDI. This position of trust involves managing all aspects of internal operations, optimizing administrative functions, and developing policies and procedures that promote sustainability and operational excellence. By enabling our research team to achieve their goals, you will drive the organization’s mission forward. https://lnkd.in/gvxEfbu4 #childhoodcancerresearch #operationsmanager #cctdi #hillsborooregon

Register now for the 2025 Pediatric Cancer Nanocourse, happening August 4th through 8th at cc-TDI's Portland area lab! This unique course is open to students, patients, and family members. It features a blend of insightful lectures and a hands-on project where you will present a new drug concept for pediatric cancer clinical trials. The week will culminate in an exciting "pitch" to clinical trialists from the University of Utah phase I clinical trial program! Register here: https://lnkd.in/g4VPNZJA #uofupedhemonc #cctdi #nanocourse #universityofutah

This week, the BD Biosciences team is installing our new cell sorter! This cutting-edge technology will allow us to precisely isolate and target cells, enabling us to analyze them in detail and identify new treatments and pathways for experimental design. Our heartfelt appreciation goes out to BD (Becton, Dickinson and Company) for making this possible for cc-TDI. We are incredibly thankful and eager to use this technology as we push our research forward. #bdbiosciences #cctdi #givingbackchildhood #cellsorter #newtechnology

At cc-TDI, we're making strides towards better treatments for pediatric brain cancers—and we wanted to provide a quick update on some of our latest research on medulloblastoma and diffuse intrinsic pontine glioma (DIPG). Medulloblastoma Research: We recently submitted a manuscript focused on IGF1R inhibition and a novel way to personalize drug delivery in medulloblastoma. This work, now in its second round of reviewer critiques, and we're hopeful for publication soon. This progress could eventually lead to a new treatment to prevent progression of new spinal metastases, and a more personalized way to ensure therapeutic levels of drug reach existing tumors. DIPG Treatment Exploration: Our team is diving into promising IL-13 receptor antibody-drug conjugate (ADC) as a potential treatment of DIPG—a rare and aggressive pediatric brain tumor. This work follows our prior research (Svalina et al published in Scientific Reports) with the practical applications of getting medicine to the tumors in a clinically feasible way. This therapy could also have important implications for medulloblastoma as well. We're excited about the progress being made in the area of brain cancers, and we are so grateful for your continued support in making this research possible. Stay tuned for more updates as we continue our mission to advance treatments for children like Andrew, Lyla THE LYLA NSOULI FOUNDATION FOR CHILDREN'S BRAIN CANCER RESEARCH, Jack, Keith, and countless other angels deserving hope. Previous published research: https://lnkd.in/gVKkd5yM #dipgawareness #childhoodcancerresearch #givingbackchildhood #cctdi #braincancerresearch

We proudly announce the publication "DNA methylation patterns are influenced by Pax3::Foxo1 expression and developmental lineage in rhabdomyosarcoma tumors" in the Journal of Pathology. Led by Dr. Wenyue Sun at the National Intitutes Of Health (NIH), in collaboration with cc-TDI, this study uncovers important insights into the genetic drivers of rhabdomyosarcoma (RMS). Key findings are that cell-of-origin may play a critical role in how the cancer behaves. A link to the article can be found here: https://lnkd.in/gWfCAUDd This publication is a testament to the power of collaboration—stemming from a 2014 call to action at Cold Spring Harbor Laboratory, inspired by the fight of young T.J. Arcati. It marks the sixth publication in a series of impactful research papers resulting from the collaboration between Dr. Barr's lab at NIH and cc-TDI. A huge thank you to our family partners, including Ava’s Army, Team Brad, The Kristian Project, and Carson Confronts Cancer, for their support in advancing this research. #childhoodcancerresearch #givingbackchildhood #cctdi #rhabdomyosarcoma #collaboration

Do you know a student desiring to make a difference in the fight against childhood cancer? Applications for 2025 summer internships with cc-TDI are open through January 31, 2025! Students will help uncover how childhood cancers work and play a critical role in the potential development of life-saving treatments. cc-TDI offers a 2-16 week mentored experience with a modest stipend. Science and engineering-focused college students, as well as exceptional high school students (16+), are encouraged to apply. We’ll also consider one student aged 14-15 for a 2-4 week internship. The application deadline is January 31, 2025, with selections announced in February. Our past interns have gone on to attend top universities like Stanford University, Harvard University, University of California, Berkeley, and Brown University, and work with industry leaders like Genentech, Loxo@Lilly, and Harvard. Many of them have also won nationally competitive grants to advance their careers! To Apply: Send your resume (3.7+ GPA minimum), transcript, and 3 references to Charles at [email protected]. This is your chance to contribute to cutting-edge research and gain invaluable experience. Join us in making a real impact! #InternshipOpportunity #STEM #ChildhoodCancerResearch #FutureLeaders #ScienceCareers #MakeADifference #ChildhoodCancer

Thank you for honoring our heroes this season by investing in research. Your generosity helped us surpass our triple match challenge and successfully raise more than $175,000 during year end—that is 145% of our year end goal! Your partnership has been a driving force in advancing childhood cancer research. Some of our biggest milestones this year include: 1. Launching a groundbreaking partnership with Team KOODAC, a global team focused on developing novel protein degrader therapeutics to target previously undruggable drivers primarily for rhabdomyosarcoma, and secondarily for Ewing sarcoma. 2. Publishing 7 peer-reviewed papers in the areas of rhabdomyosarcoma, epithelioid sarcoma, hepatoblastoma, and the use of AI in cancer research, with 8 more nearing publication. 3. Expanding our research team expertise by hiring 3 talented MS and PhD researchers, and increasing a growing network of global collaborators working to amplify our impact. 4. Investing $1M in new technology, thanks to the State of Oregon. 5. Receiving support from over 600 individuals and families, 23 companies, and 22 foundations, enabling us to propel 9 promising therapies aimed at offering real hope to children with cancer. None of this would be possible without you. Your commitment ensures that we can continue to explore new frontiers in childhood cancer research and provide children and families with the science-justified hope they need for a brighter tomorrow. On behalf of the cc-TDI team, thank you for making a difference! Wishing you a happy and healthy start to 2025! #childhoodcancerresearch #HopeInAction #cctdi #givingbackchildhood #cancerresearch #rhabdomyosarcoma #honorheroes

As we reach the end of this season of giving, we continue to honor the strength and resilience of our cc-TDI heroes—heroes like Megan, who faced rhabdomyosarcoma (RMS) with unwavering resolve. Megan was determined to be remembered as "the girl who did something." And she did. In the midst of her fight, Megan raised over $1.5 million for RMS research and founded the Citizen Scientist Project for Rhabdomyosarcoma Cures, empowering families to collaborate with researchers in the testing and prioritizing of FDA-approved treatments for use in RMS patients. Her legacy continues through the Megan's Mission Foundation and the Megan Bugg Global Rhabdomyosarcoma Research Lab at cc-TDI. "Working alongside patient advocates gives us invaluable insight into the patient experience and is the closest we get to seeing how our research impacts lives. Meeting with families each week reinforces the urgency of new breakthroughs for the children and families we serve."— Alina Teuber, PhD, cc-TDI Researcher. As we enter 2025, the need for support is more urgent than ever. Your donation today directly funds breakthroughs that will give children a brighter, healthier future. Thank you for standing with us and heroes like Megan. We’re excited for the progress your support will make possible in the new year! Give today at: https://lnkd.in/gJnwHqHt #YearEndGiving #childhoodcancerresearch #megansmission #givingbackchildhood #cctdi #rhabdomyosarcoma

As we look toward 2025, the future of federal funding for childhood cancer research is uncertain—and that makes our mission more urgent than ever. With just 4 days left to give in 2024, your support is CRITICAL in helping us accelerate life-saving research for children battling cancer. At cc-TDI, we rely on the generosity of partners joining our mission. Partners like Darcee, who has turned her grief into action. After losing her son, Keith, in 2016, Darcee created HeroUp for Children's Cancer, a superhero-themed race series that brings together hundreds of supporters every year to raise funds for cancer research. "We support childhood cancer research at cc-TDI because they care as deeply about fighting childhood cancer as we do. It’s close to our hearts and to theirs and we feel that as a family.” - Darcee, Keith's Mom As 2024 comes to a close, there’s still time to join Darcee and countless other heroes who are fueling our mission. Your gift by December 31st will help push research forward and bring us closer to new, more effective treatments for childhood cancer. Together, we can create a future where every child has the chance to live a full and healthy life. Donate now and be part of the change:ttps://https://lnkd.in/gJnwHqHt

Today, we honor our hero Brittney—a forever 5-year-old girl whose parents, and their community of Brittney's Believers, turned their grief into action by creating the Brittney Project at cc-TDI. This pilot initiative focuses on identifying compounds that specifically target embryonal rhabdomyosarcoma (ERMS), the same cancer that took Brittney's life. cc-TDI is now testing three promising compounds on a broad range of ERMS cell lines to move from lab-based studies to real-world applications in tissue environments, taking us one step closer to potential treatments. With just 9 days left in 2024, there's still time to make a powerful impact. Every donation made through December 31st will be tripled—dollar-for-dollar, up to $50,000—by a generous matching donor! Your gift will help fund cutting-edge research, bringing us closer to life-saving treatments. Join us in honoring Brittney and other heroes around the world affected by this devastating disease. Together, we accelerate research in 2025! ??Triple your today! https://lnkd.in/gJnwHqHt #BrittneyProject #ERMSresearch #ChildhoodCancerAwareness #TripleYourImpact #GiveForACure #rhabdoresearch